{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:02:05Z","timestamp":1782475325180,"version":"3.54.5"},"reference-count":34,"publisher":"Media Sphere Publishing House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a devastating disease that is the leading genetic cause of death in infants and young children. It includes a broad spectrum of phenotypes that are classified into clinical groups based on the age of onset and maximum motor function achieved. The most common form of SMA is due to a defect in the survival motor neuron 1 gene (SMN1) localized to 5q11.2\u2014q13.3. The development of clinical symptoms and disease progression is thought to be due to decreased levels of survival motor neuron (SMN) protein. SMA type 1 results in almost inevitable mortality within the first 2 years of life. The first two drugs approved globally for the treatment of SMA were the antisense oligonucleotide nusinersen (Spinraza), and the gene therapy onasemnogene abeparvovec-xioi (Zolgensma). Both interventions have approval and restrictions on use in different countries around the world. Despite these approved therapies, the medical unmet need in SMA (the majority of patients with SMA are not on a disease-modifying therapy) remains high with therapies in the pipeline to address some of the remaining limitations. The third and more recently approved drug for SMA is risdiplam (Evrysdi), an orally administered, centrally and peripherally distributed small molecule that modulates SMN2 pre-mRNA splicing toward the production of full-length SMN2 mRNA to increase functional SMN protein levels. In Russia the drug risdiplam was approved for use on November 26, 2020 with indications for the treatment of SMA in patients aged 2 months and older, and in 2023 the indications were expanded \u2014 use is allowed starting from the birth. Risdiplam is widely distributed into the CNS and peripheral tissues including muscles. Following risdiplam administration, SMN protein levels compared with baseline levels increase between 2- and 6-fold depending on the SMA phenotype treated. The risdiplam clinical development program currently has four ongoing clinical trials assessing its safety and efficacy. Clinical trials included more than 450 patients receiving risdiplam to date, has been well tolerated and no treatment-related safety findings leading to study withdrawal have been observed. Data from real clinical practice \u2014 more than 11.000 patients worldwide receive therapy with risdiplam, also confirm the safety and good tolerability of the drug.<\/jats:p>","DOI":"10.17116\/jnevro202412402145","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T12:07:15Z","timestamp":1710158835000},"page":"45","source":"Crossref","is-referenced-by-count":2,"title":["Risdiplam for the treatment of spinal muscular atrophy"],"prefix":"10.17116","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-2752","authenticated-orcid":false,"given":"D.V.","family":"Vlodavets","sequence":"first","affiliation":[{"name":"Veltischev Clinical Pediatric Research Institute of Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202412402145-1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"key-10.17116\/jnevro202412402145-2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13786"},{"key":"key-10.17116\/jnevro202412402145-3","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447"},{"key":"key-10.17116\/jnevro202412402145-4","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190424"},{"key":"key-10.17116\/jnevro202412402145-5","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"key-10.17116\/jnevro202412402145-6","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.12.131"},{"key":"key-10.17116\/jnevro202412402145-7","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2014.587"},{"key":"key-10.17116\/jnevro202412402145-8","doi-asserted-by":"publisher","DOI":"10.2741\/3670"},{"key":"key-10.17116\/jnevro202412402145-9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1250127"},{"key":"key-10.17116\/jnevro202412402145-10","unstructured":"RG7916 granted orphan drug designation in the U.S. for the treatment of spinal muscular atrophy [news release]. PTC Therapeutics, Inc. Jan 6, 2017"},{"key":"key-10.17116\/jnevro202412402145-11","unstructured":"Risdiplam. National Center for Biotechnology Information. PubChem Database.  https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/118513932"},{"key":"key-10.17116\/jnevro202412402145-12","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00460"},{"key":"key-10.17116\/jnevro202412402145-13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00406"},{"key":"key-10.17116\/jnevro202412402145-14","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw062"},{"key":"key-10.17116\/jnevro202412402145-15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"key-10.17116\/jnevro202412402145-16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2009965"},{"key":"key-10.17116\/jnevro202412402145-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102047"},{"key":"key-10.17116\/jnevro202412402145-18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00339-8"},{"key":"key-10.17116\/jnevro202412402145-19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.07.199"},{"key":"key-10.17116\/jnevro202412402145-20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00367-7"},{"key":"key-10.17116\/jnevro202412402145-21","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51239"},{"key":"key-10.17116\/jnevro202412402145-22","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00444-1"},{"key":"key-10.17116\/jnevro202412402145-23","unstructured":"A study to investigate safety, tolerability, PK, PD and efficacy of risdiplam (RO7034067) in infants with Type1 spinal muscular atrophy (FIREFISH) (NCT02913482).  https:\/\/clinicaltrials.gov\/study\/NCT02913482"},{"key":"key-10.17116\/jnevro202412402145-24","unstructured":"A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) in Type 2 and 3 spinal muscular atrophy (SMA) participants (SUNFISH) (NCT02908685). Available 05-02-2024.  https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02908685"},{"key":"key-10.17116\/jnevro202412402145-25","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11560-1"},{"key":"key-10.17116\/jnevro202412402145-26","unstructured":"An open-label study to investigate the safety, tolerability, and pharmacokinetics\/pharmacodynamics of risdiplam (RO7034067) in adult and pediatric patients with spinal muscular atrophy (NCT03032172). Available 05-02-2024.  https:\/\/stanfordhealthcare.org\/trials\/a\/NCT03032172.html"},{"key":"key-10.17116\/jnevro202412402145-27","unstructured":"A study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (RAINBOWFISH) (NCT03779334). Available 05-02-2024.  https:\/\/clinicaltrials.gov\/study\/NCT03779334"},{"key":"key-10.17116\/jnevro202412402145-28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.07.094"},{"key":"key-10.17116\/jnevro202412402145-29","unstructured":"New Genentech Data for Evrysdi Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with SMA \u2014 Cure SMA June 11, 2021. Presented at the 2021 Virtual SMA Research & Clinical Care Meeting from June 9-11, 2021. Available 05-02-2024.  https:\/\/www.curesma.org\/genentech-data-for-evrysdi-researcher-meeting-2021"},{"key":"key-10.17116\/jnevro202412402145-30","unstructured":"Instructions for medical use of the drug Evrysdi. Registration number LP-006602. (In Russ.). Available 05.02.2024. https:\/\/grls.rosminzdrav.ru\/Grls_View_v2.aspx?routingGuid=dde5212f-2f4c-4754-a9b8-87559a5aef48&t"},{"key":"key-10.17116\/jnevro202412402145-31","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2384"},{"key":"key-10.17116\/jnevro202412402145-32","unstructured":"Biogen Inc. Spinraza (nusinersen) US prescribing information. Available 05.02.24.  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf"},{"key":"key-10.17116\/jnevro202412402145-33","unstructured":"Novartis Gene Therapies Inc. Zolgensma (onasemnogene abeparvovec-xioi) US prescribing information. Available 05.02.24.  https:\/\/www.fda.gov\/media\/126109\/download"},{"key":"key-10.17116\/jnevro202412402145-34","doi-asserted-by":"crossref","unstructured":"Sivaramakrishnan M, McCarthy KD, Campagne S, et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nature Com. 2018;8(1):1-8","DOI":"10.1038\/s41467-017-01559-4"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T05:00:47Z","timestamp":1745384447000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2024\/2\/1199772982024021045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,11]]}},"alternative-id":["10.17116\/jnevro202412402145"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202412402145","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}